DCAF13 and hepatocellular carcinoma: Previous studies have shown that DCAF13 is amplified in various tumors, such as hepatocellular carcinoma (Cao et al., 2017), breast cancer (Wang et al., 2019), and osteosarcoma (Chen et al., 2018).